Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 275 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment of Type I Diabetes Mellitus. Clear all
Terminated Phase 2 Interventional Results available

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379
View directory record Official record
Conditions
Solid Tumor, Unresectable or Metastatic Melanoma
Interventions
CX-072, Ipilimumab
Drug
Lead sponsor
CytomX Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-Loop Glucagon Administration For Hypoglycemia Treatment

NCT02181127
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glucagon-only Bionic Pancreas
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Not applicable Interventional Results available

Diabetes Journey: An Adolescent Adherence Barriers Intervention

NCT04404556
View directory record Official record
Conditions
Type 1 Diabetes, Adherence, Patient
Interventions
Diabetes Journey, Enhanced Standard of Care
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Three-way, Cross-over Closed-loop Exercise Study

NCT02241889
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin pump therapy, Closed-loop Artificial Pancreas Controller
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Not applicable Interventional

Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care

NCT00194558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Internet co-management module
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 39 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus

NCT01082120
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2010 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Early Phase 1 Interventional

Early Markers of Disease and Response to Therapy

NCT04118153
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Abatacept
Drug
Lead sponsor
Sandra Lord, MD
Other
Eligibility
6 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Not applicable Interventional

Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms in Adolescents With Type 1 Diabetes Mellitus

NCT03655067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Depressive Symptoms
Interventions
CATCH-IT
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Jul 24, 2026, 9:31 AM EDT
Recruiting Phase 2 Interventional

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

NCT06455319
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Anti-thymocyte globulin (ATG), verapamil extended release capsule, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 4 Interventional

Lantus in the Treatment of Type 1 Diabetes Children

NCT00206401
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Lantus and short acting analogs Vs NPH and short acting analogs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 2 Interventional

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

NCT03911557
View directory record Official record
Conditions
Tumor, Solid
Interventions
Durvalumab and Tremelimumab
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Type 1 Diabetes

NCT01049412
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Chula Vista, California • Atlanta, Georgia • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 24, 2026, 9:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 24, 2026, 9:31 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

NCT06609356
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions
Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

ADJUnct Semaglutide Treatment in Type 1 Diabetes

NCT05537233
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Viral N. Shah
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Aurora, Colorado • West Des Moines, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 24, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Jul 24, 2026, 9:31 AM EDT
Terminated No phase listed Observational

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

NCT01767831
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iBOLUSED
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Jul 24, 2026, 9:31 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®

NCT01898286
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
DiaPep277®
Drug
Lead sponsor
Andromeda Biotech Ltd.
Industry
Eligibility
18 Years to 47 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Jul 24, 2026, 9:31 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

NCT01843374
View directory record Official record
Conditions
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions
Tremelimumab, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 24, 2026, 9:31 AM EDT